The Clinically Silent Pandemic: A Review of Aflatoxin B1 Exposure and its Role in Hepatocellular Carcinoma and Immune Suppression View PDF

AFB1 exposure represents a significant yet often underrecognized public health concern, particularly due to its role in the development of HCC and its capacity to induce immune suppression [1-6]. The literature underscores the multifaceted impact of AFB1 on human health, emphasizing its carcinogenic potential, mechanisms of immune modulation, and the synergistic effects with other risk factors such as hepatitis virus infections [7-11]. The biological properties of AFB1 are central to understanding its carcinogenicity. As detailed by Cha?a?kiewicz et al. [10], AFB1 and its metabolite M1 are implicated in cancer development through their ability to form DNA adducts, leading to mutations. Specifically, AFB1 exposure has been associated with mutations in the p53 tumor suppressor gene, which is a critical event in hepatocarcinogenesis. The analysis of AFB1-lysine adducts in human populations provides a biomarker for assessing exposure levels, highlighting the public health relevance of monitoring AFB1 in food commodities [11].

Epidemiological studies have demonstrated a clear link between AFB1 exposure and increased risk of HCC, especially in regions with high dietary contamination [12-16]. For instance, in Africa, the synergistic effect of AFB1 and hepatitis B virus (HBV) infection significantly elevates HCC risk [17]. The interaction between these two factors appears to amplify carcinogenic processes, possibly through mechanisms involving DNA damage and immune suppression. The meta-analysis cited in Balan et al. [18] further supports this, indicating that reducing AFB1 exposure could lead to a substantial decrease (approximately 23%) in HCC incidence in high-risk areas. This underscores the importance of food safety interventions and exposure mitigation strategies. Beyond its carcinogenic effects, AFB1 exerts profound influence on the immune system. The degree of immune suppression associated with AFB1 exposure is a critical aspect of its pathogenic profile. As discussed by Kuhn and Ghannoum [19], immune suppression not only facilitates persistent infections but also impairs the body’s ability to surveil and eliminate emerging tumor cells. The clinical implications of this immune modulation are significant, as they may contribute to the progression and aggressiveness of HCC. The immune suppression induced by AFB1 may involve alterations in cytokine production, lymphocyte function, and overall immune responsiveness, although the precise mechanisms require further elucidation.

At the cellular level, endoplasmic reticulum stress and the unfolded protein response are implicated in AFB1-induced hepatocarcinogenesis [20-24]. The literature highlights that endoplasmic reticulum stress plays a dual role: initially protective but ultimately contributing to tumor progression when dysregulated [25]. AFB1-induced DNA damage and oxidative stress can trigger endoplasmic reticulum stress pathways, which may support tumor cell survival by preventing apoptosis. This adaptive response enables malignant hepatocytes to proliferate despite genotoxic insults, thereby facilitating tumor development. The unfolded protein response’s role in supporting tumor cell metabolism and proliferation underscores its potential as a therapeutic target in AFB1-related HCC. The molecular interplay between AFB1 exposure, endoplasmic reticulum stress, and metabolic dysregulation further complicates the pathogenesis of HCC. As outlined by Luna-Marco et al. [25], the unfolded protein response can promote tumor cell survival by modulating cellular metabolism and resisting apoptosis. This adaptive mechanism may be exploited by hepatocytes under chronic AFB1 exposure, leading to malignant transformation. The integration of these pathways suggests that AFB1 not only causes direct DNA damage but also creates a cellular environment conducive to tumor growth through metabolic reprogramming and stress response pathways. The public health implications of AFB1 exposure are compounded by its prevalence in various food commodities, including nuts, spices, and processed foods [18, 26]. The widespread contamination underscores the need for effective monitoring and regulation to prevent long-term health consequences. The evidence suggests that interventions aimed at reducing dietary AFB1 levels could significantly decrease HCC incidence, especially in high-risk populations. The meta-analytical data indicates a 23% reduction in HCC with lowered AFB1 exposure emphasizes the potential impact of such measures.

In addition to its carcinogenic effects, AFB1’s role in immune suppression may facilitate persistent infections with hepatitis viruses, particularly HBV and hepatitis C virus (HCV), which are wellestablished risk factors for HCC [17]. The interaction between viral infections and AFB1 exposure appears to be synergistic, with each factor exacerbating the other’s carcinogenic potential [8, 27-29]. This synergy complicates disease management and highlights the importance of integrated approaches that address both viral infections and environmental toxins.

Overall, literature collectively underscores AFB1 as a critical environmental carcinogen with a dual role in promoting HCC and impairing immune function. Its ability to induce DNA mutations, particularly in the p53 gene, coupled with its capacity to modulate cellular stress responses and immune pathways, positions AFB1 as a key contributor to the ‘silent pandemic’ of liver cancer. Addressing AFB1 exposure through food safety measures, public health interventions, and targeted therapies could substantially reduce the burden of HCC worldwide, especially in regions where exposure is endemic. The complex interplay between AFB1, immune suppression, and viral infections necessitates a comprehensive approach to mitigate its impact on global health.